ENAH and breast carcinoma: ENAH (also known as MENA or hMena), is a member of the enabled/vasodilator‐stimulated phosphoprotein (Ena/VASP) family,10 and has been proven to be highly expressed in various cancer types, such as breast cancer,11 gastric cancer,12 esophageal squamous cell carcinoma,13 ovarian cancer,14 etc. In the studies of OSCC, the high expression of ENAH in OSCC was associated with epithelial‐to‐mesenchymal transition (EMT) induced tumor progression and metastasis, as well as poor prognosis in OSCC patients.15, 16